Validation of polypharmacy process measures in inpatient schizophrenia care

Schizophrenia Bulletin

Volumn 30, Issue 4, 2004, Pages 1023-1033

  Janssen, Birgit ^a,b   Weinmann, Stefan ^a   Berger, Mathias ^c   Gaebel, Wolfgang ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Rheinische Kliniken Dusseldorf   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antipsychotic agents; Polypharmacy; Quality assurance; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; BENPERIDOL; BROMPERIDOL; CHLORPROMAZINE; CLOPENTHIXOL; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROTHIPENDYL; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG; ZOTEPINE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL ACETATE;

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MENTAL HOSPITAL; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL STATUS; THOUGHT DISORDER; TREATMENT OUTCOME;

EID: 16344368818     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007117     Document Type: Article

References (36)

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 154(4 Suppl):1-63, 1997.
2. Awad, A.G., and Hogan, T.P. Early treatment events and prediction of response to neuroleptics in schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry, 9(5-6):585-588, 1985.
3. Baldessarini, R.J., and Tarazi, F.I. Drugs and the treatment of psychiatric disorders: Antipsychotic and antimaniac agents. In: Hardman, J.G.; Limbird, L.E.; and Gilman, A.G., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill, 2001. pp. 485-520.
4. Buchanan, R.W.; Kreyenbuhl, J.; Zito, J.M.; and Lehman, A. The schizophrenia PORT pharmacological treatment recommendations: Conformance and implications for symptoms and functional outcome. Schizophrenia Bulletin, 28(1):63-73, 2002.
5. Burns, T.; Chabannes, J.P.; and Demyttenaere, K. Switching antipsychotic medications: General recommendations and switching to amisulpride. Current Medical Research and Opinion, 18(4):201-208, 2002.
6. Centorrino, F.; Eakin, M.; Bahk, W.M.; Kelleher, J.P.; Goren, J.; Salvatore, P.; Egli, S.; and Baldessarini, R.J. Inpatient antipsychotic drug use in 1998, 1993, and 1989. American Journal of Psychiatry, 159(11):1932-1935, 2002.
7. Covell, N.H.; Jackson, C.T.; Evans, A.C.; and Essock, S.M. Antipsychotic prescribing practices in Connecticut's public mental health system: Rates of changing medications and prescribing styles. Schizophrenia Bulletin, 28(1):17-29, 2002.
8. Endicott, J.; Spitzer, R.L.; Gleiss, J.L.; and Cohen, J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33:766-771, 1976.
9. Gaebel, W. Prediction research of outcome in neuroleptic treatment-definitions and concepts. In: Gaebel, W., and Awad, A.G., eds. Prediction of Neuroleptic Treatment Outcome in Schizophrenia-Concepts and Methods. Vienna, NY: Springer, 1994. pp. 15-26.
10. Gaebel, W.; Pietzcker, A.; Ulrich, G.; Schley, J.; and Muller-Oerlinghausen, B. Predictors of neuroleptic treatment response in acute schizophrenia: Results of a treatment study with perazine. Pharmacopsychiatry, 21(6):384-386, 1988.
11. Hermann, R.C.; Finnerty, M.; Provost, S.; Palmer, R.H.; Chan, J.; Lagodmos, G.; Teller, T.; and Myrhol, B.J. Process measures for the assessment and improvement of quality of care for schizophrenia. Schizophrenia Bulletin, 28(1):95-104, 2002b.
12. Hermann, R.C., and Palmer, R.H. Common ground: A framework for selecting core quality measures for mental health and substance abuse care. Psychiatric Services, 53(3):281-287, 2002.
13. Kay, S.R. Positive and Negative Syndromes in Schizophrenia. New York, NY: Brunner and Mazel, 1991.
14. Kay, S.R.; Fiszbein, A.; and Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2):261-276, 1987.
15. Kingsbury, S.J.; Yi, D.; and Simpson, G.M. Psychopharmacology: Rational and irrational polypharmacy. Psychiatric Services, 52(8):1033-1036, 2001.
16. Kinon, B.J.; Basson, B.R.; Gilmore, J.A.; Malcolm, S.; and Stauffer, V.L. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Journal of Clinical Psychiatry, 61:833-840, 2000.
17. Lehman, A.F., and Steinwachs, D.M. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophrenia Bulletin, 24(1):11-20, 1998a.
18. Lehman, A.F., and Steinwachs, D.M. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24(1):1-10, 1998b.
19. Marder, S.R.; Essock, S.M.; Miller, A.L.; Buchanan, R.W.; Davis, J.M.; Kane, J.M.; Lieberman, J.; and Schooler, N.R. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia Bulletin, 28(1):5-16, 2002.
20. Miller, A.L., and Craig, C.S. Combination antipsychotics: Pros, cons, and questions. Schizophrenia Bulletin, 28(1):105-109, 2002.
21. National Collaborating Centre for Mental Health on Behalf of the National Institute for Clinical Excellence (NICE). Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Clinical guideline 1. London, U.K.: Abba Litho Sales, 2002.
22. Owen, R.R.; Thrush, C.R.; Kirchner, J.E.; Fischer, E.P.; and Booth, B.M. Performance measurement for schizophrenia: Adherence to guidelines for antipsychotic dose. International Journal for Quality in Health Care, 12(6):475-482, 2000.
23. Popkin, M.K.; Lurie, N.; Manning, W.; Harman, J.; Callies, A.; Gray, D.; and Christianson, J. Changes in the process of care for Medicaid patients with schizophrenia in Utah's Prepaid Mental Health Plan. Psychiatric Services, 49(4):518-523, 1998.
24. Rosenheck, R.A.; Desai, R.; Steinwachs, D.; and Lehman, A. Benchmarking treatment of schizophrenia: A comparison of service delivery by the national government and by state and local providers. Journal of Nervous and Mental Disease, 188(4):209-216, 2000.
25. Sartorius, N.; Fleischhacker, W.W.; Gjerris, A.; Kern, U.; Knapp, M.; Leonhard, B.E.; Lieberman, J.A.; López-Ibor, J.J.; van Raay, B.; Tomquist, E.; and Twomey, E. The usefulness and use of second-generation antipsychotic medications-an update. Current Opinion in Psychiatry, 16(Suppl 1):S1-S44, 2003.
26. Shiloh, R.; Zemishlany, Z.; Aizenberg, D.; Radwan, M.; Schwartz, B.; Dorfman-Etrog, P.; Modai, I.; Khaikin, M.; and Weizman, A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry, 171(Dec):569-573, 1997.
27. Startup, M.; Jackson, C.; and Bendix, S. The concurrent validity of the Global Assessment of Functioning (GAF). British Journal of Clinical Psychology, 41(Pt 4):417-422, 2002.
28. Statistical Package for Social Sciences, version 10.1. Munich, Germany: SPSS Inc., 2001.
29. Tapp, A.; Wood, A.E.; Secrest, L.; Erdmann, J.; Cubberley, L.; and Kilzieh, N. Combination antipsychotic therapy in clinical practice. Psychiatric Services, 54(1):55-59, 2003.
30. Taylor, D.M.; Mace, S.; and Mir, S. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. International Journal of Psychiatry in Clinical Practice, 4:41-46, 2000.
31. Van Putten, T.; May, P.R.A.; and Marder, S.R. Subjective response to antipsychotic drugs. Archives of General Psychiatry, 38(2):189-190, 1981.
32. Waddington, J.L.; Youssef, H.A.; and Kinsella, A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173:325-329, 1998.
33. Weinmann, S.; Janssen, B.; and Gaebel, W. Switching antipsychotics in inpatient schizophrenia care-predictors and outcome. Journal of Clinical Psychiatry, 65(8):1099-1105, 2004.
34. Woods, S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry, 64(6):663-667, 2003.
35. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva, Switzerland: World Health Organization, 1992.
36. Wyatt, R.J. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17(2):325-351, 1991.